UK Inflammatory Bowel Disease (IBD) audit: Round 4 (2012 - 2014)

Data from the UK IBD audit requires careful interpretation and the information should not be looked at in isolation when assessing standards of care. The results should be interpreted within the context of the fact that many sites entered a relatively small number of cases to the audit and therefore all percentages should be viewed alongside the actual number of cases submitted. As a reflection of this a very small number of events can change percentages quite dramatically and hence caution is advised.

Data relating to round 4 of the UK IBD audit (2012-2014) biological therapies, organisational, inpatient care and inpatient experience audit elements are being made available, data for adult and paediatric sites is provided separately.

The purpose of the biological therapies audit is to measure the efficacy, safety and appropriate use of biological therapies in patients with inflammatory bowel disease in the UK and to capture the views of patients on their quality of life at intervals during their treatment. This is a prospective audit with data collection taking place in ‘real time’ during the clinic appointment. Participating sites were asked to identify and enter data on patients newly started on biological therapies between 12 September 2011 and 28 February 2014.

The organisational audit data provided gives an indication of how an IBD service is resourced and organised in relation to the IBD Standards, they are not a definition of clinical quality. Participating sites were required to meet as a multidisciplinary team and sit together to undertake data collection for the audit, via a web based assessment tool. Sites were asked to consider their service provision ‘as at’ 31 December 2013.

The inpatient care audit data provided gives information about the process of care provided to IBD inpatients. These data items were identified by the UK IBD audit steering group as reflecting the questions from the round 4 inpatient care dataset of particular importance to IBD patients. In the inpatient care audit participating sites were asked to prospectively identify and audit up to 50 consecutive admissions of adults and young people with ulcerative colitis between 1 January and 31 December 2013. For each audited admission entered to the web tool, each site was asked to generate an inpatient experience questionnaire that was to be given to the patient on discharge. Each site was provided with freepost envelopes to allow and encourage patients to return their questionnaires to the project team at the Royal College of Physicians. Alternatively patients could enter their own data directly with the provision of a web link to the UK IBD audit web tool. Each questionnaire had a unique cross reference code that could be linked back to the admission that had been entered in the inpatient care audit.

These data do not include any data about individual patients nor does it contain any patient identifiable data. The remit of the UK IBD audit covers the whole of the UK, however data here are provided at ‘site’ level for all participating sites, in England only. The term ‘site’ refers to an IBD Service that may be run across one or more hospitals within an NHS organisation, therefore an NHS Trust in England can comprise of one or more sites.

英国炎症性肠病审计数据需谨慎解读，评估护理标准时，不应孤立地看待相关信息。结果应结合事实进行解读，即众多机构向审计提交的案件数量相对较少，因此所有百分比均应与提交的实际案件数一并考量。鉴于极少数事件可对百分比产生显著影响，故需保持警惕。

英国炎症性肠病审计第四轮（2012-2014年）的生物治疗、组织架构、住院护理和住院体验审计要素的相关数据现已公开，成人及儿科机构的数据分别提供。

生物治疗审计的目的是衡量英国炎症性肠病患者生物治疗的疗效、安全性和合理应用，并捕捉患者在其治疗期间不同时间点的生命质量观。这是一项前瞻性审计，数据收集在‘实时’的门诊预约中进行。参与机构被要求识别并录入2011年9月12日至2014年2月28日期间新开始接受生物治疗的患者的数据。

提供的管理审计数据表明，炎症性肠病服务在资源分配和组织架构上如何符合炎症性肠病标准，它们并非临床质量的定义。参与机构被要求以多学科团队的形式集合在一起，通过基于网络的评估工具进行审计数据收集。机构被要求考虑其服务提供情况至2013年12月31日。

提供的住院护理审计数据提供了关于为炎症性肠病住院患者提供护理过程的信息。这些数据项由英国炎症性肠病审计指导小组认定为反映第四轮住院护理数据集中对炎症性肠病患者特别重要的问题。在住院护理审计中，参与机构被要求前瞻性地识别和审计2013年1月1日至12月31日期间成人及年轻人溃疡性结肠炎患者的最多50例连续入院记录。对于每个通过网络工具录入的审计入院记录，每个机构都被要求生成一份住院体验问卷，该问卷应在患者出院时发放。每个机构都提供了免费邮资信封，以便并鼓励患者将问卷寄回皇家医学院的项目团队。或者，患者可以直接通过提供的英国炎症性肠病审计网络工具链接输入自己的数据。每个问卷都有一个唯一的交叉引用代码，可以追溯到住院护理审计中录入的入院记录。

这些数据不包含任何关于个别患者的信息，也不包含任何可识别患者的数据。英国炎症性肠病审计的职责范围涵盖整个英国，但此处提供的数据仅限于英格兰的参与机构在‘机构’层面的数据。‘机构’一词指可能由一个或多个医院组成的国民健康服务体系下的炎症性肠病服务，因此英格兰的国民健康信托可能包含一个或多个机构。